Latest News and Press Releases

NeOnc(NASDAQ: NTHI) is rapidly emerging as a development-stage neuro-oncology innovator

our names that have emerged as closely watched stories spanning biotechnology, AI, aerospace, communications, and digital infrastructure

NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026The Phase 1 monotherapy...

Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026The Phase 1 monotherapy...

Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) --...

Cavli Wireless to unveil CQM211 5G NR Advanced module at Embedded World 2026, offering up to 3.4 Gbps, OpenWrt OS, and in-built GNSS for high-bandwidth IoT

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation...